In Brief: Nellcor
Nellcor: Pulse oximeter and patient monitoring equipment manufacturer enters the home therapy product market by acquiring privately held Pierre Medical, a French manufacturer of home respiratory products. Pierre, which markets its noninvasive ventilators, sleep apnea therapy systems and oxygen concentrators primarily in France and Germany, will become part of Nellcor's EdenTec home health care subsidiary. EdenTec, based in Eden Prairie, Minnesota, currently manufactures and markets apnea monitors, sleep apnea diagnostic devices and oximetry products for use in the home. Acquisition of the 50-employee Pierre Medical "is an excellent strategic fit for Nellcor and EdenTec as we expand our presence in home health care and in international markets," the firm says. Terms of the deal were not disclosed...
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
More from Medtech Insight
Only 16% of venture capital general partners in Europe are women, and only 9% of those have actual investment power. Thena Capital is aiming to "redefine the image of a venture capitalist."
The General Services Administration’s updated list of “assets identified for accelerated disposition” does not include any buildings at the agency’s headquarters in White Oak, MD after its original list of “non-core” government properties for disposal had more than half the buildings on campus.
Exer Labs Inc.’s website marketed its AI-based Exer Scan app to “screen and treat Parkinson’s, TB, Cerebral Palsy and more.” But those claims went well beyond what was allowed under the product’s 510(k) clearance, US regulators say.